Back

Safety of discontinuing anticoagulation after atrial fibrillation ablation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation in atrial fibrillation: one size doesn't fit all Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rahul Tripathi

Stony Brook University Hospital, Stony Brook (United States of America)

6 More presentations in this session

Presentation thumbnail
Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates
Mr C. Ursu (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Who missed out on anticoagulation? a nationwide temporal analysis of patients with new-onset atrial fibrillation and no anticoagulation
Mr A. Luojus (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis
Doctor E. Habib (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
Long-term real-world outcomes of edoxaban in atrial fibrillation patients with and without prior ischaemic stroke: A 4-year follow-up analysis from ETNA-AF Europe
Professor R. De Caterina (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis
Mr O. Makdah (Cottbus, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation in atrial fibrillation: one size doesn't fit all

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Interrupted vs uninterrupted direct oral anticoagulants compared with uninterrupted vitamin K antagonists for atrial fibrillation ablation - A meta-analysis of safety
thumbnail
Congress Presentation
Safety outcomes of catheter ablation versus antiarrhythmic drugs in atrial fibrillation: a comprehensive systematic review and meta-analysis
thumbnail
Congress Presentation
Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources